Epicardial Adipose Tissue-Targeted DApagliflozin for Reducing Electrical Remodeling in Atrial Fibrillation

Starting soon · Not applicable

Conditions studied: Atrial Fibrillation (AF)

In brief

Persistent atrial fibrillation (PeAF) is associated with a high risk of recurrence following catheter ablation despite advances in ablation technology and strategies. Beyond electrophysiological mechanisms, increasing evidence suggests that atrial structural and inflammatory remodeling plays a pivotal role in the initiation and maintenance of AF, particularly in persistent forms. Epicardial adipose tissue (EAT) is a metabolically active visceral fat depot located between the myocardium and visceral pericardium. EAT shares a common microcirculation with the underlying atrial myocardium and exerts paracrine and vasocrine effects through the secretion of pro-inflammatory cytokines, adipokines, and profibrotic mediators. Increased EAT volume or thickness has been consistently associated with AF burden, atrial fibrosis, left atrial enlargement, and a higher risk of AF recurrence after catheter ablation. Sodium-glucose cotransporter 2 inhibitors (SGLT2i) have demonstrated pleiotropic cardiovascular benefits beyond glucose lowering, including reduction in visceral adiposity, attenuation of systemic and local inflammation, and favorable effects on cardiac remodeling. Observational studies and randomized trials in patients with diabetes or heart failure suggest that SGLT2i therapy reduces incident AF and AF recurrence after ablation. However, the effect of SGLT2i in non-diabetic, non-heart failure patients-particularly those with increased EAT as a distinct pathophysiological substrate-remains unclear.This trial is designed to evaluate whether dapagliflozin, administered peri-ablation, can reduce atrial arrhythmia recurrence in PeAF patients with increased EAT but without class I indications for SGLT2i. This targeted approach aims to provide mechanistic and clinical evidence supporting metabolic-inflammatory modulation as an adjunctive strategy to catheter ablation.

Key facts

Study ID

NCT07331727

Run by

Shanghai Chest Hospital

People needed

280

Starts

2026-01-01

Expected to finish

2026-12-31

Last updated by the study team

2026-01-12

Who can join

Age: 18 and older, up to 80. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age 18-80 years;
• Diagnosis of persistent atrial fibrillation (continuous AF >7 days and ≤5 years);
• Planned first-time catheter ablation for AF;
• No class I indications for dapagliflozin, defined as:
• No diabetes mellitus;
• No history of heart failure (HFrEF, HFmrEF, or HFpEF);
• No chronic kidney disease (eGFR ≥60 mL/min/1.73 m²);
• Evidence of increased epicardial adipose tissue on cardiac CT or cardiac MRI, defined according to pre-specified imaging thresholds;
• Ability to provide written informed consent.

You may not qualify if…

• Duration of persistent AF >5 years;
• Left atrial anteroposterior diameter >50 mm on transthoracic echocardiography;
• Prior AF catheter ablation or surgical ablation;
• Current or recent (within 3 months) use of any SGLT2 inhibitor;
• Severe structural heart disease (e.g., hypertrophic cardiomyopathy, rheumatic valvular disease, dilated cardiomyopathy);
• Contraindications to catheter ablation (e.g., left atrial thrombus, active infection);
• Estimated glomerular filtration rate <60 mL/min/1.73 m²;
• Type 1 diabetes or history of diabetic ketoacidosis;
• Pregnancy or breastfeeding;
• Any condition deemed by investigators to make study participation inappropriate.

Where it is running

• Shanghai Chest Hospital — Shanghai, China

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.